A User’s Guide to Cannabinoid Therapies in Oncology

Maida, Vincent; Daeninck, Paul

doi:10.3747/co.23.3487

Cited by 62 publications

(66 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior studies using synthetic THC analogues [9][10][11] have not incorporated the whole cannabis plant and, therefore, cannot evaluate other substances, such as terpenes and flavonoids, that may enhance or provide additional therapeutic properties. 49 At the same time, the numerous potential risks of cannabis in this population, including drug-drug interactions, 17,50 infections, 16,51-54 sinopulmonary side effects, 18,[54][55][56] neuropsychiatric sequelae, 19,57 and unintended overdoses/poisonings, [58][59][60][61] argue for rigorous safety studies. Currently, however, the US government continues to classify cannabis as a schedule I drug, and this restricts federal funding for safety studies and those assessing its therapeutic use in this population.…”

Section: Discussionmentioning

confidence: 99%

Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

Pergam

Woodfield

Lee

et al. 2017

Cancer

222

188

View full text Add to dashboard Cite

BACKGROUNDCannabis is purported to alleviate symptoms related to cancer treatment, although the patterns of use among cancer patients are not well known. This study was designed to determine the prevalence and methods of use among cancer patients, the perceived benefits, and the sources of information in a state with legalized cannabis.METHODSA cross‐sectional, anonymous survey of adult cancer patients was performed at a National Cancer Institute–designated cancer center in Washington State. Random urine samples for tetrahydrocannabinol provided survey validation.RESULTSNine hundred twenty‐six of 2737 eligible patients (34%) completed the survey, and the median age was 58 years (interquartile range [IQR], 46‐66 years). Most had a strong interest in learning about cannabis during treatment (6 on a 1‐10 scale; IQR, 3‐10) and wanted information from cancer providers (677 of 911 [74%]). Previous use was common (607 of 926 [66%]); 24% (222 of 926) used cannabis in the last year, and 21% (192 of 926) used cannabis in the last month. Random urine samples found similar percentages of users who reported weekly use (27 of 193 [14%] vs 164 of 926 [18%]). Active users inhaled (153 of 220 [70%]) or consumed edibles (154 of 220 [70%]); 89 (40%) used both modalities. Cannabis was used primarily for physical (165 of 219 [75%]) and neuropsychiatric symptoms (139 of 219 [63%]). Legalization significantly increased the likelihood of use in more than half of the respondents.CONCLUSIONSThis study of cancer patients in a state with legalized cannabis found high rates of active use across broad subgroups, and legalization was reported to be important in patients' decision to use. Cancer patients desire but are not receiving information about cannabis use during their treatment from oncology providers. Cancer 2017;123:4488‐97. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

show abstract

Section: Discussionmentioning

confidence: 99%

Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

Pergam

Woodfield

Lee

et al. 2017

Cancer

222

188

View full text Add to dashboard Cite

show abstract

“…In the treatment of an oncologically ill patient, cannabinoids are used primarily for symptomatic treatment (pain, nausea, vomiting, and anorexia) (7). In the pain management, cannabinoids are effective for chronic neuropathic pain (7), their synergistic effect with opioids is assumed (8), although they do not appear to have any effect on the treatment of acute pain (9). Recently, we have seen publications that consider the direct antitumor effect of cannabinoids and the involvement of cannabinoid receptors in curative therapy of an oncologically ill patient.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, we have seen publications that consider the direct antitumor effect of cannabinoids and the involvement of cannabinoid receptors in curative therapy of an oncologically ill patient. Anti-proliferative, antimetastatic, antiangiogenic, and proapoptotic effects of cannabinoids are considered (7). In this review article, we will focus on the role of cannabinoids as antitumor agents.…”

Section: Introductionmentioning

confidence: 99%

The role of cannabinoids in the treatment of cancer

Večeřa¹,

Gabrhelik²,

Prášil³

et al. 2020

BLL

View full text Add to dashboard Cite

The aim of this review article is to summarize current knowledge about the role of cannabinoids and cannabinoid receptors in tumor disease modulation and to evaluate comprehensively the use of cannabinoids in cancer patients. METHOD: According to the PRISMA protocol, we have included data from a total of 105 articles. RESULTS: Cannabinoids affect cancer progression by three mechanisms. The most important mechanism is the stimulation of autophagy and affecting the signaling pathways leading to apoptosis. The most important mechanism of this process is the accumulation of ceramide. Cannabinoids also stimulate apoptosis by mechanisms independent of autophagy. Other mechanisms by which cannabinoids affect tumor growth are inhibition of tumor angiogenesis, invasiveness, metastasis, and the modulation of the anti-tumor immune response. CONCLUSION: In addition to the symptomatic therapy of cancer patients, the antitumor effects of cannabinoids (whether in monotherapy or in combination with other cancer therapies) have promising potential in the treatment of cancer patients. More clinical trials are needed to demonstrate the antitumor effect of cannabinoids (Tab. 1, Fig. 1, Ref. 167).

show abstract

“…However, these articles and websites extrapolate in vitro study results and preclinical work into humans without any basis in fact. 25 To date, no study has explored the evidence to answer queries from patients on the effects of THC on urological cancers. Hence, this review has elucidated the state of current evidence in various tumours, including renal, bladder, prostate, and testicular neoplasms.…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers

Gandhi

Vasisth

Kapoor

2017

CUAJ

View full text Add to dashboard Cite

Introduction: The palliative effects of cannabis sativa (marijuana), which include appetite stimulation, attenuation of nausea and emesis, and pain relief, are well known. The active components of cannabis sativa (cannabinoids) and their derivatives have received growing interest due to their diverse pharmacological activities, such as cell growth inhibition and tumour regression. The aim of this review is to look at the current evidence on the antiproliferative effects of cannabinoids in urological malignancies, including renal, prostate, bladder, and testicular cancers. Methods: We conducted a systematic review of studies exploring the effect of cannabinoids on tumour activity, including all study types except expert opinions. A formal search was run on Medline database from 1946 to September 2016, along with a hand-search on PubMed for relevant studies. Results: The search yielded a total of 93 studies from Medline and PubMed, of which 23 studies were included in the final analysis. To date, there are various in vitro studies elucidating the potential mechanism of action of cannabinoids for urological cancers, along with population-based studies specifically for testicular malignancies. To date, no clinical trials have been conducted for urological cancer patients.Conclusions: These results demonstrate that the role of endocannabinoids for urological malignancies is an area of active research. Further research is required not only to evaluate the crosstalk between cancer signaling pathways and cannabinoids, but also large randomized clinical studies with urological patients need to be conducted before cannabinoids can be introduced as potential therapeutic options for urological neoplasms.

show abstract

A User’s Guide to Cannabinoid Therapies in Oncology

Cited by 62 publications

References 94 publications

Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

The role of cannabinoids in the treatment of cancer

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers

Contact Info

Product

Resources

About